HURA Stock Overview
A clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
TuHURA Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.89 |
| 52 Week High | US$7.93 |
| 52 Week Low | US$1.80 |
| Beta | 0 |
| 1 Month Change | -7.38% |
| 3 Month Change | -15.07% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -38.25% |
Recent News & Updates
Shareholder Returns
| HURA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.4% | -2.1% | 5.1% |
| 1Y | n/a | -18.2% | 10.6% |
Return vs Industry: Insufficient data to determine how HURA performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how HURA performed against the US Market.
Price Volatility
| HURA volatility | |
|---|---|
| HURA Average Weekly Movement | 19.5% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: HURA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HURA's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 19 | Jim Bianco | www.tuhurabio.com |
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company’s lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-specific antibody-peptide conjugates and antibody-drug conjugates targeting Myeloid Derived Suppressor Cells.
TuHURA Biosciences, Inc. Fundamentals Summary
| HURA fundamental statistics | |
|---|---|
| Market cap | US$179.09m |
| Earnings (TTM) | -US$22.65m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.5x
P/E RatioIs HURA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HURA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$22.65m |
| Earnings | -US$22.65m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did HURA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/14 19:12 |
| End of Day Share Price | 2025/05/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TuHURA Biosciences, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Burns | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |
| John Vandermosten | Zacks Small-Cap Research |